We have defined a number of strategic innovation priorities based on consumer and customer needs across all our business segments. These include providing novel ingredient solutions as well as novel premix and market-ready solutions that deliver nutritional support in segments such as healthy aging and women’s health.
In 2023, we accelerated the shift from fish oil to algal sources with the launch of life’s®OMEGA O3020, and led the market in infant nutrition innovation in HMOs.
- Other notable innovation achievements this year included:
- Increasing the bioavailability of vitamins with our ampli® vitamins range
- The publication by the European Food Safety Authority (EFSA) of the conversion factor for calcidiol (25-hydroxyvitamin D3) in its scientific opinion on the tolerable upper intake level for vitamin D – a major regulatory process milestone for obtaining approval for ampli-D® in the European Union
- Providing new solutions for one of the world’s biggest nutrient-related disorders with Tolerase® G, the first and only enzyme demonstrated to effectively break down residual gluten molecules
- Pioneering in biotics-based gut health with the Humiome® brand, an innovative range of ‘Health from the gut’ solutions. Shaped by microbiome science and consumer needs, Humiome® comprises prebiotics, probiotics and postbiotics, along with multi-ingredient custom solutions delivered via microbiome-targeted technology
